The plan would cost $2.2m on top of the $7m already spent annually on the needle exchange programme and hepatitis C assessment and treatment.
The WHO defined elimination as reducing new chronic cases by 90 per cent and deaths by 65 per cent compared to 2015.
Verrall said hepatitis C was both preventable and curable, but symptoms often did not appear until the damage had already been done.
"Around 45,000 New Zealanders have hepatitis C but only around half know they have it," she said.
"Without treatment, most people will develop progressive liver damage. Hepatitis C is the leading cause of liver transplants in New Zealand, and the second leading cause of liver cancer - behind hepatitis B."
She said many people with the virus were in "our most marginalised communities" and faced barriers to testing and treatment including social stigma.
The direct-acting antiviral drug Maviret, which had been funded since February 2019, had fewer side effects than previous treatments and could cure up to 98 per cent of chronic hepatitis C infections, she said.
"Maviret has been a real game-changer, but funding drugs alone won't achieve elimination. We need to make sure we find everyone who is at risk or has hepatitis C, offer them a test and to treat them."